行情

TROV

TROV

Trovagene
NASDAQ

实时行情|Nasdaq Last Sale

1.660
-0.030
-1.78%
盘后: 1.630 -0.03 -1.81% 17:11 02/21 EST
开盘
1.690
昨收
1.690
最高
1.698
最低
1.570
成交量
19.39万
成交额
--
52周最高
9.65
52周最低
0.8800
市值
1,285.23万
市盈率(TTM)
-0.4997
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测TROV价格均价为14.50,最高价位23.00,最低价为6.00。

EPS

TROV 新闻

更多
  • Trovagene down 10% premarket on mid-stage onvansertib data
  • seekingalpha · 02/13 19:20
  • Trovagene down 10% premarket on mid-stage onvansertib data
  • Seeking Alpha - Article · 02/13 14:20
  • NTAP, AEG among premarket losers
  • Seeking Alpha - Article · 02/13 14:17
  • The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
  • Benzinga · 02/13 13:05

所属板块

生物技术和医学研究
+0.37%
制药与医学研究
+0.54%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

TROV 简况

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 developed high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase Ib/II clinical trial in patients with AML underway.
展开

微牛提供TrovaGene Inc(NASDAQ-TROV)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的TROV股票新闻,以帮助您做出投资决策。